Marko Tkach
Endocrinology, Diabetes & Metabolism · Fall River, MANPI 1386252310
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 105 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 15.3% — the pattern of someone who eats at a lot of different presentations.
Across 105 payments — averaging $69.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Amgen$862
- Abbott$649
- Johnson & Johnson$606
- Bayer$455
- Novo Nordisk$418
- plus $3K from 28 others
What the payments were for
- Food & beverage$7,340100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 13 | $1,120 |
| Amgen | 9 | $862 |
| Abbott | 5 | $649 |
| Johnson & Johnson(2 entities) | 13 | $606 |
| Bayer | 6 | $455 |
| Novo Nordisk | 6 | $418 |
| Sanofi-aventis U.S. LLC | 5 | $322 |
| Corcept Therapeutics | 8 | $257 |
| Avanir Pharmaceuticals, Inc. | 2 | $245 |
| Teva Pharmaceuticals USA, Inc. | 2 | $238 |
| GSK | 2 | $223 |
| E.r. Squibb & Sons, L.L.C. | 2 | $215 |
| Boehringer Ingelheim | 2 | $212 |
| Alkermes, Inc. | 2 | $193 |
| Kyowa Kirin, Inc. | 4 | $160 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $134 |
| Neurocrine Biosciences, Inc. | 2 | $132 |
| Medtronic | 2 | $132 |
| Radius Health, Inc. | 2 | $106 |
| Sanofi | 1 | $104 |
| Ultragenyx Pharmaceutical Inc. | 1 | $104 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $101 |
| Kowa Pharmaceuticals America, Inc. | 1 | $98 |
| Amneal Pharmaceuticals LLC | 2 | $41 |
| Tandem Diabetes Care, Inc. | 2 | $32 |
| Sequel Med Tech, LLC | 1 | $25 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $24 |
| Novartis | 1 | $22 |
| IBSA Pharma Inc. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Recordati_rare_diseases_inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $15 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,340 in reported general payments places this provider in the 80th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
See all endocrinology, diabetes & metabolism providers in Massachusetts →
Other endocrinology, diabetes & metabolism in Fall River
- Tamer YacoubFall River$775K
- Kishore LakshmanFall River$9K
- Jason GagliaBoston$2.4M
- Vanita ArodaBoston$482K
- Michael RosenblattBoston$447K
- Steven RussellBoston$445K
- Nitin TrivediWorcester$403K
- Beverly BillerBoston$346K
- Christos MantzorosBoston$243K
- Peter ButlerFlorence$216K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.